Evidence map›Paper›PMID 31702394›Full record

ArticleFuture medicinal chemistry2019

Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors.

Jie-Huan Zhang, Madhusoodanan Mottamal, Hai-Shan Jin, Shanchun Guo, Yan Gu, Guangdi Wang, Li-Ming Zhao

Abstract read
In one paragraph

Article in Future medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Design, synthesis, biological andBiomedical reports · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie-Huan ZhangSchool of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, Jiangsu, China.
Madhusoodanan MottamalRCMI Cancer Research Center & Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Hai-Shan JinSchool of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, Jiangsu, China.
Shanchun GuoRCMI Cancer Research Center & Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Yan GuSchool of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, Jiangsu, China.
Guangdi WangRCMI Cancer Research Center & Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Li-Ming ZhaoSchool of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, Jiangsu, China.ORCID 0000-0002-7917-8754

Funding

Xavier RCMI Renewal Application-Research Infrastructure CoreU54MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI Guangdi Wang, Christopher Williams · 2019 to 2026
$41.9M
Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
NIMHD NIH HHS G12 MD007595NIMHD NIH HHS U54 MD007595
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DesignCarbon-13 Magnetic Resonance SpectroscopyHistone Deacetylase InhibitorsHydroxamic AcidsMolecular Docking SimulationProton Magnetic Resonance SpectroscopySpectrometry, Mass, Electrospray IonizationStructure-Activity RelationshipSulfonamidesbelinostatHistone Deacetylase InhibitorsHydroxamic AcidsSulfonamidesanticancer activitiesdrug designmolecular dockingstructure–activity relationshipsynthesis

Identifiers

PMID31702394
PMCPMC7607388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.